A Phase 2 Study to Investigate Ubamatamab With and Without REGN7075 in Treatment-Experienced Participants With Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)
Latest Information Update: 15 Sep 2025
At a glance
- Drugs REGN 7075 (Primary) ; Sarilumab (Primary) ; Ubamatamab (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- Sponsors Regeneron Pharmaceuticals
Most Recent Events
- 15 Sep 2025 New trial record